Risedronate in the treatment of Murine Chagas' disease

Boumediene Bouzahzah, Linda A. Jelicks, Stephen A. Morris, Louis M. Weiss, Herbert B. Tanowitz

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Risedronate, a bisphosphonate, was used to treat CD-1 mice infected with the Brazil strain of Trypanosoma cruzi. When given by subcutaneous injection 3 times/week, there was a significant reduction in mortality, however, the myocardial pathology and right ventricular dilation was unchanged in these mice compared to control animals. In C57BL/6 mice infected with the Tulahuen strain, there was no change in mortality in response to risedronate treatment. These data suggest that this class of compounds has activity against T. cruzi in vivo and illustrate the utility of imaging and pathologic studies as adjuncts in the evaluation of therapeutic compounds as treatments for experimental Chagas' disease. In addition, it underscores the need to use different strains of T. cruzi.

Original languageEnglish (US)
Pages (from-to)184-187
Number of pages4
JournalParasitology Research
Volume96
Issue number3
DOIs
StatePublished - Jun 2005

Fingerprint

Chagas disease
Chagas Disease
Trypanosoma cruzi
mice
Mortality
Diphosphonates
subcutaneous injection
Subcutaneous Injections
Inbred C57BL Mouse
Brazil
Dilatation
Therapeutics
image analysis
Pathology
therapeutics
Risedronate Sodium
animals

ASJC Scopus subject areas

  • Parasitology

Cite this

Bouzahzah, B., Jelicks, L. A., Morris, S. A., Weiss, L. M., & Tanowitz, H. B. (2005). Risedronate in the treatment of Murine Chagas' disease. Parasitology Research, 96(3), 184-187. https://doi.org/10.1007/s00436-005-1331-9

Risedronate in the treatment of Murine Chagas' disease. / Bouzahzah, Boumediene; Jelicks, Linda A.; Morris, Stephen A.; Weiss, Louis M.; Tanowitz, Herbert B.

In: Parasitology Research, Vol. 96, No. 3, 06.2005, p. 184-187.

Research output: Contribution to journalArticle

Bouzahzah, B, Jelicks, LA, Morris, SA, Weiss, LM & Tanowitz, HB 2005, 'Risedronate in the treatment of Murine Chagas' disease', Parasitology Research, vol. 96, no. 3, pp. 184-187. https://doi.org/10.1007/s00436-005-1331-9
Bouzahzah, Boumediene ; Jelicks, Linda A. ; Morris, Stephen A. ; Weiss, Louis M. ; Tanowitz, Herbert B. / Risedronate in the treatment of Murine Chagas' disease. In: Parasitology Research. 2005 ; Vol. 96, No. 3. pp. 184-187.
@article{b231d73a2edf40d0a9c9967e62c9698e,
title = "Risedronate in the treatment of Murine Chagas' disease",
abstract = "Risedronate, a bisphosphonate, was used to treat CD-1 mice infected with the Brazil strain of Trypanosoma cruzi. When given by subcutaneous injection 3 times/week, there was a significant reduction in mortality, however, the myocardial pathology and right ventricular dilation was unchanged in these mice compared to control animals. In C57BL/6 mice infected with the Tulahuen strain, there was no change in mortality in response to risedronate treatment. These data suggest that this class of compounds has activity against T. cruzi in vivo and illustrate the utility of imaging and pathologic studies as adjuncts in the evaluation of therapeutic compounds as treatments for experimental Chagas' disease. In addition, it underscores the need to use different strains of T. cruzi.",
author = "Boumediene Bouzahzah and Jelicks, {Linda A.} and Morris, {Stephen A.} and Weiss, {Louis M.} and Tanowitz, {Herbert B.}",
year = "2005",
month = "6",
doi = "10.1007/s00436-005-1331-9",
language = "English (US)",
volume = "96",
pages = "184--187",
journal = "Parasitology Research",
issn = "0932-0113",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Risedronate in the treatment of Murine Chagas' disease

AU - Bouzahzah, Boumediene

AU - Jelicks, Linda A.

AU - Morris, Stephen A.

AU - Weiss, Louis M.

AU - Tanowitz, Herbert B.

PY - 2005/6

Y1 - 2005/6

N2 - Risedronate, a bisphosphonate, was used to treat CD-1 mice infected with the Brazil strain of Trypanosoma cruzi. When given by subcutaneous injection 3 times/week, there was a significant reduction in mortality, however, the myocardial pathology and right ventricular dilation was unchanged in these mice compared to control animals. In C57BL/6 mice infected with the Tulahuen strain, there was no change in mortality in response to risedronate treatment. These data suggest that this class of compounds has activity against T. cruzi in vivo and illustrate the utility of imaging and pathologic studies as adjuncts in the evaluation of therapeutic compounds as treatments for experimental Chagas' disease. In addition, it underscores the need to use different strains of T. cruzi.

AB - Risedronate, a bisphosphonate, was used to treat CD-1 mice infected with the Brazil strain of Trypanosoma cruzi. When given by subcutaneous injection 3 times/week, there was a significant reduction in mortality, however, the myocardial pathology and right ventricular dilation was unchanged in these mice compared to control animals. In C57BL/6 mice infected with the Tulahuen strain, there was no change in mortality in response to risedronate treatment. These data suggest that this class of compounds has activity against T. cruzi in vivo and illustrate the utility of imaging and pathologic studies as adjuncts in the evaluation of therapeutic compounds as treatments for experimental Chagas' disease. In addition, it underscores the need to use different strains of T. cruzi.

UR - http://www.scopus.com/inward/record.url?scp=20944439686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20944439686&partnerID=8YFLogxK

U2 - 10.1007/s00436-005-1331-9

DO - 10.1007/s00436-005-1331-9

M3 - Article

VL - 96

SP - 184

EP - 187

JO - Parasitology Research

JF - Parasitology Research

SN - 0932-0113

IS - 3

ER -